TY - JOUR
T1 - VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection
AU - Gebremariam, Teclegiorgis
AU - Wiederhold, Nathan P.
AU - Fothergill, Annette W.
AU - Garvey, Edward P.
AU - Hoekstra, William J.
AU - Schotzinger, Robert J.
AU - Patterson, Thomas F.
AU - Filler, Scott G.
AU - Ibrahim, Ashraf S.
N1 - Publisher Copyright:
© 2015, American Society for Microbiology. All Rights Reserved.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with R. arrhizus var. arrhizus and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis.
AB - We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with R. arrhizus var. arrhizus and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis.
UR - http://www.scopus.com/inward/record.url?scp=84954496267&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84954496267&partnerID=8YFLogxK
U2 - 10.1128/AAC.01437-15
DO - 10.1128/AAC.01437-15
M3 - Article
C2 - 26369977
AN - SCOPUS:84954496267
SN - 0066-4804
VL - 59
SP - 7815
EP - 7817
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 12
ER -